Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids?

Forensic Science International

Volumn 257, Issue , 2015, Pages e6-e11

  Hess, C ^a   Stockhausen, S ^a   Kernbach Wighton, G ^a   Madea, B ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

AB FUBINACA; Diabetic coma; Ketoacidosis; Synthetic cannabinoids

Indexed keywords

CANNABINOID; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; LACTIC ACID; ACETONE; DESIGNER DRUG; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AORTA ANGUSTA; AORTA DISEASE; ARTICLE; ASCENDING AORTA; AUTOPSY; BRAIN EDEMA; CASE REPORT; CAUSE OF DEATH; CEREBROSPINAL FLUID ANALYSIS; DIABETIC KETOACIDOSIS; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG INTOXICATION; DRUG USE; FATTY LIVER; FEMORAL VEIN; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; LACTATE BLOOD LEVEL; LIQUID CHROMATOGRAPHY; LUNG CONGESTION; LUNG EDEMA; MALE; MASS SPECTROMETRY; PETECHIA; PRIORITY JOURNAL; SEPARATION TECHNIQUE; VENOUS BLOOD; BLOOD; CHEMISTRY; FATALITY; FORENSIC TOXICOLOGY; VITREOUS BODY;

ACETONE; ADULT; CANNABINOIDS; DESIGNER DRUGS; DIABETIC KETOACIDOSIS; FATAL OUTCOME; FORENSIC TOXICOLOGY; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LACTIC ACID; MALE; VITREOUS BODY;

EID: 84954197048     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2015.08.012     Document Type: Article

References (43)

1. Mir A., Obafemi A., Young A., Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011, 128(6):e1622-e1627.
2. Behonick G., Shanks K.G., Firchau D.J., Mathur G., Lynch C.F., Nashelsky M., Jaskierny D.J., Meroueh C. Four postmortem case reports with quantitative detection of the synthetic cannabinoid 5F-PB-22. J. Anal. Toxcol. 2014, 38(8):559-562.
3. Ibrahim S., Al-Saffar F., Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep. Cardiol. 2014, 2014:120607.
4. Gugelmann H., Gerona R., Li C., Tsutaoka B., Olson K.R., Lung D. 'Crazy Monkey' poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin. Toxicol. 2014, 52(6):635-638.
5. Hoyte C.O., Jacob J., Monte A.A. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann. Emerg. Med. 2012, 60(4):435-438.
6. Schneir A.B., Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J. Med. Toxicol. 2012, 8:62-64.
7. (accessed 05.05.15). https://legal-high-inhaltsstoffe.de/.
8. Karinen R., Tuv S.S., Øiestad E.L., Vindenes V. Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids. Forensic Sci. Int. 2015, 246:98-103.
9. Langer N., Lindigkeit R., Schiebel H.M., Ernst L., Beuerle T. Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: a snapshot of the German situation in the autumn of 2012. Drug Test Anal. 2014, 6(1-2):59-71.
10. Sobolevsky T., Prasolov I., Rodchenkov G. Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue. Drug Test. Anal. 2015, 7(2):131-142.
11. Kavanagh P., Grigoryev A., Savchuk S., Mikhura I., Formanovsky A. UR-144 in products sold via the Internet: identification of related compounds and characterization of pyrolysis products. Drug Test Anal. 2013, 5(8):683-692.
12. Louis A., Peterson B.L., Couper F.J. XLR-11 and UR-144 in Washington state and state of Alaska driving cases. J. Anal. Toxicol. 2014, 38(8):563-568.
13. Lemos N.P. Driving under the influence of synthetic cannabinoid receptor agonist XLR-11. J. Forensic Sci. 2014, 59(6):1679-1683.
14. Huffman J.W., Zengin G., Wu M.J., Lu J., Hynd G., Bushell K., Thompson A.L., Bushell S., Tartal C., Hurst D.P., Reggio P.H., Selley D.E., Cassidy M.P., Wiley J.L., Martin B.R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg. Med. Chem. 2005, 13(1):89-112.
15. A. Makriyannis, H. Deng, Cannabimimetic Indole Derivatives, WO patent 200128557, (2007) granted 06.07.01.
16. C. Hess, C. Schoeder, B. Madea, C.E. Mueller, Cannabinoid Receptor Affinities of Synthetic Cannabinoids on the Illicit Drug Market. Unpublished results.
17. Wiley J.L., Compton D.R., Dai D., Lainton J.A., Phillips M., Huffman J.W., Martin B.R. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 1998, 285(3):995-1004.
18. Wiley J.L., Marusich J.A., Lefever T.W., Antonazzo K.R., Wallgren M.T., Cortes R.A., Patel P.R., Grabenauer M., Moore K.N., Thomas B.F. AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing Δ(9)-tetrahydrocannabinol-like effects in mice. J. Pharmacol. Exp. Ther. 2015, 354(3):328-339.
19. Coe J.I. Postmortem chemistry of blood, cerebrospinal fluid, and vitreous humor. Leg. Med. Annu. 1977, 1976:55-92.
20. Forrest AR A.R. ACP broadsheet no 137. Obtaining samples at post mortem examination for toxicological and biochemical analyses. J. Clin. Pathol. 1993, 46:292-296.
21. Traub F. Methode zur Erkennung von tödlichen Zuckerstoffwechselstörungen. an der Leiche (Diabetes mellitus und hypoglykämie). Zent. Allg. Pathol. 1969, 112:390-399.
22. Hess C., Thomas A., Thevis M., Stratmann B., Quester W., Tschoepe D., Madea B., Musshoff F. Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 2012, 404(6-7):1813-1822.
23. Jeppsson J.O., Kobold U., Barr J. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin. Chem. Lab. Med. 2002, 40:78.
24. Kneisel S., Auwärter V. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J. Mass. Spectrom. 2012, 47(7):825-835.
25. Fraser A.D., Worth D. Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Forensic Sci. Int. 2003, 133:26-31.
26. Wohlfarth A., Pang S., Zhu M., Gandhi A.S., Scheidweiler K.B., Liu H.F., Huestis M.A. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin. Chem. 2013, 59(11):1638-1648.
27. Hess C., Madea B., Daldrup T., Musshoff F. Determination of hypoglycaemia induced by insulin or its synthetic analogues post mortem. Drug Test. Anal. 2013, 5(9-10):802-807.
28. Thevis M., Thomas A., Schänzer W., Ostman P., Ojanperä I. Measuring insulin in human vitreous humour using LC-MS/MS. Drug Test. Anal. 2012, 4(1):53-56.
29. Zilg B., Alkass K., Berg S., Druid H. Postmortem identification of hyperglycemia. Forensic Sci. Int. 2009, 185:89.
30. Karlovsek M.Z. Diagnostic values of combined glucose and lactate values in cerebrospinal fluid and vitreous humour-our experiences. Forensic Sci. Int. 2004, 146:S19.
31. Palmiere C., Sporkert F., Vaucher P. Is the formula of Traub still up to date in antemortem blood glucose level estimation?. Int. J. Legal Med. 2012, 126:407.
32. Palmiere C., Bardy D., Mangin P., Werner D. Postmortem diagnosis of unsuspected diabetes mellitus. Forensic Sci. Int. 2013, 226:160.
33. Kernbach G., Picht S., Brinkmann B., Puschel K. Initial results of postmortem diagnosis of diabetes mellitus by Hb A1 determination. Z. Rechtsmed. 1983, 90:303.
34. Gormsen H., Lund A. The diagnostic value of postmortem blood glucose determinations in cases of diabetes mellitus. Forensic Sci. Int. 1985, 28:103.
35. H. Falk, Praktische Sektionsdiagnostik mit Schnellmethoden, in: K. Pfeifer (Ed.), Veb Georg Thieme, Leipzig, 1964.
36. Schibel N. Zur postmortalen Diagnose von Störungen des Kohlenhydratstoffwechsels (Doctora thesis) 2007, Institute of Legal Medicine, Berlin.
37. Demirci H., Coşar R., Çiftçi Ö., Sari I.K. Atypical diabetic ketoacidosis: case report. Balkan Med. J. 2015, 32(1):124-126.
38. Seely K.A., Prather P.L., James L.P., Moran J.H. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse. Mol. Interv. 2011, 11:36-51.
39. Simmons J., Cookman L., Kang C., Skinner C. Three cases of spice exposure. Clin. Toxicol. (Phila) 2011, 49:431-433.
40. Romero-Zerbo S.Y., Garcia-Gutierrez M.S., Suárez J., Rivera P., Ruz-Maldonado M., Vida F., Rodriguez de Fonseca J., Manzanares F.J., Bermúdez-Silva Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice. J. Neuroendocrinol. 2012, 24(8):1106-1119.
41. Liu J., Zhou L., Xiong K., Godlewski G., Mukhopadhyay B., Tam J., Yin S., Gao P., Shan X., Pickel J., Bataller R., O'Hare J., Scherer T., Buettner C., Kunos G. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012, 142(5):1218-1228.e1.
42. Bermúdez-Siva F.J., Serrano A., Diaz-Molina F.J., Sánchez Vera I., Juan-Pico P., Nadal A., Fuentes E., Rodríguez de Fonseca F. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur. J. Pharmacol. 2006, 531(1-3):282-284.
43. Patel K.N., Joharapurkar A.A., Patel V., Kshirsagar S.G., Bahekar R., Srivastava B.K., Jain M.R. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Can. J. Physiol. Pharmacol. 2014, 92(12):975-983.